Email this article Clinical example of the drug pazopanib as a targeted therapy in inoperable cancer of the kidney
- Authors: Klimenko AA1, Ivanov SA1
-
Affiliations:
- ФГБУ Российский научный центр рентгенорадиологии Минздрава России, Москва
- Issue: Vol 15, No 4 (2013)
- Pages: 45-46
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26927
- ID: 26927
Cite item
Full Text
Abstract
This article is a result of their own long-term observation of the patient treatment of inoperable cancer of the kidney. As first-line therapy pazopanib is used in standard dosage. The drug belongs to the new generation of drugs that block angiogenesis and having cytoreductive effect. During treatment, the stabilization of the disease. The results of treatment can be recommended for use pazopanib treatment of kidney cancer.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A A Klimenko
ФГБУ Российский научный центр рентгенорадиологии Минздрава России, Москва
Email: oncouro@gmail.com
канд. мед. наук, ст. науч. сотр. отд-ния лаборатории урологии и андрологии хирургического отд.
S A Ivanov
ФГБУ Российский научный центр рентгенорадиологии Минздрава России, Москвад-р мед. наук, зав. урологическим отд-нием
References
- Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 г. М., 2012.
- Чубенко В.А. Осложнения таргетной терапии RUSSCO. 2012; 9: 3.
- Клименко А.А. Применение тирозинкиназных препаратов при лечении распространенного рака почки. Terra Medica 2013; 3 (73):37–41.
- Motzer R.J, Masumdar M, Bacic J et al. Survival and prognostic tratification of 670 patients with advanced renal cell сarcinoma. J Clin Oncol 1999; 17 (8): 2530–40.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer 2009; 1. http://gls/PDF/kidney.pdf
- Farrell M.A, Di Marco D.C. Imaging - guided radiofrequency ablation of solid renal tumors. AJR Amer J Roentgenol 2003; 180: 1509.
- Giberti C, Oneto F, Martorana G et al. Radical nephrectomy for renal cell carcinoma: long - term results and prognostic factors on a series of 328 cases. Eur Urol 1997; 31 (1): 40–8.
- Sternberg C.N, Davis I.D, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061–8.
- Mc Cann L, Amit O, Pandite L, Amado R.G. An indirect comparison analysis of pazopanib vs other agents in metastatic renal cell carcinoma (mR - CC). J Clin Oncol 2010; 28 (Suppl.): e15128. Abstr.
